Tempus AI, the Chicago-based precision-medicine company, agreed Monday, July 20, to acquire cancer-testing firm Personalis for $16.25 per share — a deal valued at about $1.7 billion, or roughly $1.5 billion net of the stake Tempus already held.
The strategic target: minimal residual disease
Personalis specializes in tumor-informed molecular residual disease (MRD) testing — ultra-sensitive assays that detect traces of cancer DNA in blood after treatment, catching recurrence months before imaging can. Tempus wants that capability wired directly into its AI-enabled oncology platform, which already spans genomic profiling, clinical data and treatment-matching algorithms. The companies size the US MRD opportunity at more than $20 billion.
The numbers
The $16.25 offer is a modest ~6% premium to Personalis' July 17 close — though about 28% above the unaffected 30-day volume-weighted average — which is why Tempus shares slid on the announcement while arbitrage desks shrugged. Consideration is Tempus stock plus up to 50% cash at Tempus' discretion, with the exchange ratio capped at 0.3356x. Personalis has delivered more than 35,000 molecular tests, with Q2 2026 volume of 10,384 tests, up 33% sequentially. Closing is expected in Q4 2026 at the earliest, subject to Personalis shareholder and regulatory approval.
Consolidation logic
Tempus has spent 2026 rolling up the data layers of oncology — genomics, pathology, clinical records — on the thesis that AI models trained across all of them will outperform single-assay competitors. MRD was the conspicuous gap: rivals like Natera built multibillion-dollar franchises on recurrence monitoring while Tempus partnered with, then invested in, and now buys Personalis outright.
What it signals
Healthcare AI consolidation is moving from data partnerships to full acquisitions: owning the assay, the data exhaust, and the model in one company is becoming the default playbook for AI-era diagnostics.